Ruolan Zeng
Overview
Explore the profile of Ruolan Zeng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qin L, Li Y, Zeng R, He Y, Chen X, Xiao L, et al.
Hum Vaccin Immunother
. 2024 Sep;
20(1):2408088.
PMID: 39348228
NK/T-cell lymphoma (NKTCL) is a rare type of non-Hodgkin lymphoma (NHL). Although L-asparaginase-based chemotherapy has significantly improved survival in early-stage patients, the prognosis is poor in advanced and relapsed or...
2.
Su C, Huang L, Liang L, Ou L, Lu G, Wang C, et al.
Infect Agent Cancer
. 2024 May;
19(1):25.
PMID: 38802946
This paper introduces two cases of multiple myeloma, COVID-19 infection during autologous stem cell transplantation, the treatment process, and different results of the two patients, which provides a reference for...
3.
Li Y, Chen K, Chen B, Zeng R, He Y, Wang C, et al.
Leukemia
. 2024 May;
38(7):1553-1563.
PMID: 38783159
Immunotherapy with programmed cell death 1 ligand 1 (PD-L1) blockade was effective in patients with NK/T-cell lymphoma. In addition to PD-L1, indoleamine 2,3-dioxygenase-1 (IDO1) is one of the most promising...
4.
Li Y, Li Y, Zeng R, He Y, Liang L, Ou L, et al.
J Cancer
. 2023 Nov;
14(17):3182-3190.
PMID: 37928429
Central nervous system lymphoma (CNSL) is an aggressive non-Hodgkin's lymphoma (NHL) confined to the central nervous system (CNS). Orelabrutinib is an oral second-generation Bruton tyrosine kinase (BTK) inhibitor and a...
5.
Ou L, Su C, Liang L, Duan Q, Li Y, Zang H, et al.
Hum Vaccin Immunother
. 2023 Oct;
19(3):2267865.
PMID: 37846106
CAR-T cell therapy, a novel therapeutic approach that has attracted much attention in the field of cancer treatment at present, has become the subject of many studies and has shown...
6.
Huang Y, Zeng R, Xue C, Huang Q, Yu D, Shao L, et al.
J Cancer Res Clin Oncol
. 2023 May;
149(12):9721-9726.
PMID: 37244875
Background: The prognosis of patients with angioimmunoblastic T cell lymphoma (AITL) remains dismal, with their 5-year overall survival (OS) and progression-free survival (PFS) rates of 32-41% and 18-38%, respectively. Spleen...
7.
Duan Q, Li Y, Ou L, Li Y, Zeng R, He Y, et al.
J Cancer
. 2022 Apr;
13(6):1785-1795.
PMID: 35399710
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. Treatment of DLBCL has improved greatly in recent decades, with thousands of papers published. We conducted a bibliometric analysis...
8.
Zhou H, Zhang J, Chen B, Liu H, Liu X, Sun Z, et al.
Transl Cancer Res
. 2022 Feb;
9(1):335-345.
PMID: 35117187
Background: This study aimed to investigate the association of circular RNA itchy E3 ubiquitin protein ligase (circ-ITCH) expression with disease risk, clinical characteristics, progression-free survival (PFS) and overall survival (OS)...
9.
Qin L, Li Y, He Y, Zeng R, Pan T, Zuo Y, et al.
Onco Targets Ther
. 2022 Jan;
15:1-11.
PMID: 35023929
Primary central nervous system extranodal natural killer/T-cell lymphoma (PCNS ENK/TCL) is an extremely rare lymphoma. Only 23 cases of PCNS ENK/TCL have been reported in the English literature. Due to...
10.
Li Y, Chen K, Zuo C, Zeng R, He Y, Chen X, et al.
Int J Gen Med
. 2021 Nov;
14:8399-8411.
PMID: 34819748
Purpose: Hepatosplenic T cell lymphoma (HSTCL) is a rare tumor that lacks data to guide management decisions. To shed light on the nature and therapy of the entity, we conducted...